Diabetic foot infection

Microbion Selected to Present at Advanced Wound Care Summit USA

Retrieved on: 
Monday, April 15, 2024
Safety, DFI, Amputation, Incidence, Patient, Diabetic foot infection, Diabetes, Pharmaceutical industry

BOZEMAN, MT and VANCOUVER, BC, April 15, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.

Key Points: 
  • BOZEMAN, MT and VANCOUVER, BC, April 15, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.
  • Karim Lalji, Microbion's CEO, will be presenting during the Innovation Showcase portion of the summit on April 17 at 9:30am in the Grand Ballroom.
  • The presentation will focus on topical pravibismane's clinical safety and efficacy for the treatment of moderate to severe DFI and future development plans.
  • Furthermore, the incidence of diabetic ulcer-related lower limb amputations was approximately 6-fold lower in the pooled pravibismane group compared to the placebo group (2.6% versus 15.4%).

DnaNudge secures FDA approval to deploy a Multiplex PCR platform for diagnosing four-in-one respiratory pathogens in Ghana

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Medical Devices, Infectious Diseases, Genetics, COVID-19, Biotechnology, Diabetic foot infection, FRS, DnaNudge, Vertically transmitted infection, Research, Urinary tract infection, DNA, RSV, Diabetic foot, Respiratory syncytial virus, Laureate, The Lancet, Clinical trial, Genomics, PCR, University, Medicine, Infection, Biomedicine, City, Medical research, University of Ghana, Imperial College London, RT, Partnership, RNA, Doctor of Philosophy, Quad, AI, SARS, Biomedical engineering, Life, TB, COVID, Vaccine, Medical device, Pharmaceutical industry

The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.

Key Points: 
  • The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.
  • Unlike the majority of other nucleic acid point-of-care tests based on isothermal amplification methods, the DnaNudge technology uses gold standard RT-PCR.
  • Testing samples can be collected via nasopharyngeal, nasal only or combined nose and throat swabs.
  • The unique lab-free nature of the DnaNudge system means that the test is ideal for use by healthcare professionals in any setting, including urban and rural environments.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

Retrieved on: 
Friday, September 22, 2023
Priority review, Food and Drug Administration Safety and Innovation Act, Innovation Act, IV, Prevalence, Amputation, Diabetes, QIDP, Methicillin, S. aureus, Methicillin-resistant Staphylococcus aureus, Infection, Act, MRSA, NDA, Fast Track, Osteomyelitis, ABSSSI, GAIN, Diabetic foot infection, Patient, Ulcer, Disease, DFI, Mortality, Toxic shock syndrome, Bacteria, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-positive bacteria, Food, Pharmaceutical industry, FDASIA

Oral contezolid and intravenous (IV) contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with DFI.

Key Points: 
  • Oral contezolid and intravenous (IV) contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with DFI.
  • Both products were previously granted QIDP designation and Fast Track status in 2018 for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
  • With excellent microbiological activity against common Gram-positive bacteria, contezolid and contezolid acefosamil are well positioned to benefit DFI patients, particularly due to methicillin-resistant Staphylococcus aureus (MRSA).
  • "We believe that MicuRx can offer an important new choice for DFI treatment with flexibility of oral and IV formulations."

Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections

Retrieved on: 
Thursday, August 24, 2023
DFI, Sydney, HRFS, Clinical trial, Diabetes, Amputation, Diabetic foot infection, ASX, FSE, Liverpool Hospital, Patient, Nursing, Ulcer, Old Liverpool Hospital, Safety, RCE, Pharmaceutical industry, Phase

The trial is underway at Liverpool Hospitals South West’s Sydney Limb Preservation and Wound Research Unit.

Key Points: 
  • The trial is underway at Liverpool Hospitals South West’s Sydney Limb Preservation and Wound Research Unit.
  • “The topical dosing of R327 in multiple patients in Australia’s largest DFI study is another welcomed advance to the Company’s infectious disease portfolio of clinical programs,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Each year the High-Risk Foot Service (HRFS) at Liverpool Hospital manages approximately 800 patients presenting with complex foot disease, with over 80% occurring in people with diabetes.
  • Furthermore, foot ulceration leads to 85% of diabetes-related amputations.2 Treating diabetic foot diseases in the U.S. costs $9-13 billion every year.3

The Inner Circle Acknowledges, Franklin W. Harry, DPM, as a Top Pinnacle Healthcare Professional for his contributions to in the Podiatric Field

Retrieved on: 
Tuesday, March 21, 2023
Ankle, Chin Na, Extremities, Diabetes, Barry University, Arthritis, Pharming, Patient, Wart, Foot, Quality of life, Medicine, Anil Relia, Mentorship, Multimedia, BFF, Washington University in St. Louis, Bentley, Inner circle, Wyckoff Heights Medical Center, Diabetic foot infection, Multiple, American Board of Commissioners for Foreign Missions, Best Foot Forward, DPM, Cooking, Restaurant, Child, Diagnosis, Health, Injury, Dentistry, Podiatry

ST. LOUIS, March 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Franklin W. Harry, DPM, is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to in the Podiatric Field.

Key Points: 
  • ST. LOUIS, March 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Franklin W. Harry, DPM, is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to in the Podiatric Field.
  • Dr. Harry earned a Doctor of Podiatric Medicine degree from Barry University in Miami, FL.
  • A podiatrist, also known as a podiatric physician or a foot and ankle surgeon, is a medical professional devoted to treating disorders of the foot, ankle, and lower extremities.
  • Dr. Harry is the founder of Best Foot Forward and has offices in Festus and St. Louis, MO.

Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference

Retrieved on: 
Friday, February 3, 2023
BIO, NTM, World Health Organization, Cystic fibrosis, Patient, Diabetic foot infection, WHO, Nontuberculous mycobacteria, Conference, Pharmaceutical industry

BOZEMAN, Mont., and VANCOUVER, BC, Feb. 3, 2023 /PRNewswire/ - Microbion Corporation, a clinical stage pharmaceutical company, today announced that Karim Lalji, CEO of Microbion Pharma Corp., will be presenting at the 2023 BIO CEO & Investor Conference in New York, NY.

Key Points: 
  • BOZEMAN, Mont., and VANCOUVER, BC, Feb. 3, 2023 /PRNewswire/ - Microbion Corporation, a clinical stage pharmaceutical company, today announced that Karim Lalji, CEO of Microbion Pharma Corp., will be presenting at the 2023 BIO CEO & Investor Conference in New York, NY.
  • The conference will take place February 6th to 9th at the Marriot Marquis Times Square.
  • Microbion's presentation will take place on February 6 at 3:45pm ET in the Winter Garden Room, 6th floor of the Marriot Marquis Times Square.
  • Private meetings with Microbion can be arranged through the BIO CEO & Investor Conference meeting platform or via the contact information below.